Adaptilens is a pre-clinical biotech firm located in Boston, MA. It has secured $17.5 million in Series A investment.
Perceptive Xontogeny Venture Funds (PXV Funds) led the round, and Accanto Partners, 380 Cap, and Pillar VC also contributed.
Through first-in-human studies, the business plans to use the funding to further the development of its accommodating intraocular lens (A-IOL).
It is a pre-clinical biotech firm headed by CEO and Founder Liane Clamen that aims to improve cataract surgery standards of care. The Adaptilens A-IOL is a biomimetic intraocular lens that adapts to the eye’s natural signal to focus, doing away with the need for glasses or contact lenses. It is a soft and flexible accommodating intraocular lens (A-IOL).
“The young, healthy human eye is perfectly designed, and its soft, flexible lens is what allows the eye to change power for a full range of vision. Our aim is to give a young vision-restoring biomimetic solution for the increasing number of individuals requiring cataract surgery. This money is significant because it allows our outstanding team to quickly advance the creation of our A-IOL, which is the finest in its class.”
CEO Liane Clamen
Concerning ADAPTILENS
Pre-clinical biotech startup Adaptilens, Inc. is privately held and dedicated to revolutionizing cataract surgical treatment. The first and only biomimetic intraocular lens that reacts to the eye’s natural signal to focus is the Adaptilens A-IOL, a soft and flexible accommodating intraocular lens (A-IOL) that does away with the need for glasses or contact lenses. Our goal is to bring back young eyesight and transform cataract surgery. Boston, Massachusetts is the home base of it.
